ASX ANNOUNCEMENT

Notification under section 708A(5)(e) of the Corporations Act 2001 (Cth)


Between 1 June and 5 June 2018, ImpediMed issued 865,534 new fully paid ordinary shares as a result of the exercise of options under the Company’s Employee Incentive Plan.

ImpediMed advises that:

1. The shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act and without a Product Disclosure Statement for the shares being prepared;

2. This notice is being given under section 708A(5)(e) of the Corporations Act;

3. As a disclosing entity, ImpediMed is subject to regular reporting and disclosure obligations;

4. As at the date of this notice, ImpediMed has complied with:

   (i) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and

   (ii) section 674 of the Corporations Act as it applies to the Company; and

5. As at the date of this notice, there is no excluded information of the type referred to in sections 708A(7) and 708A(8) of the Corporations Act that is required to be disclosed by the Company under 708A(6)(e) of the Corporations Act.

For and on behalf of the Board.

Leanne Ralph
Company Secretary
Media Contacts:

In Australia:
Kyahn Williamson, Buchan
T: +61 3 9866 4722
E: kwilliamson@buchanwe.com.au

In the US:
Paul Maccabee/Andy Pollen, Maccabee PR
T: +1 612-337-0087
E: paul@maccabee.com; andy@maccabee.com

About ImpediMed
Founded and headquartered in Brisbane, Australia with U.S. offices in Carlsbad, Calif. and Bloomington, Minn., ImpediMed is the world leader in the development and distribution of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status in patients. ImpediMed has the first medical device with FDA clearance in the U.S. to aid healthcare professionals to clinically assess unilateral lymphoedema of the arm and leg in women and the leg in men. For more information, visit www.impedimed.com.